title: [Treatment and prognosis of children with relapsed non-Hodgkin's lymphoma--a report from CCLSG-NHL 890 Study. Children's Cancer and Leukemia Study Group (CCLSG)].
abstract: To address the issue of salvageability in relapsed children with NHL who had all received the same frontline therapy, we retrospectively studied the treatment response and the outcome of 27 children who relapsed following the CCLSG-NHL890 protocol. The reinduction rates and 3-year survival rates (mean +/- SD) were as follows: lymphoblastic lymphoma (LB, n = 9), 44% & 17 +/- 14%; leukemia lymphoma syndrome (LLS, n = 8), 25% & 0%; large cell lymphoma (LC, n = 3) 100% & 67 +/- 27%; Burkitt's lymphoma (B, n = 7) 0% & 0%. Thus, the salvageability of LC lymphoma was good, but the outcome of Burkitt's lymphoma was very poor. CCLSG-NHL960 protocol for LB lymphomas and intensive multiagent regimens for LC lymphomas produced favorable response rates, but the effect of the high-dose Ara-C regimen for Burkitt's lymphoma was not determined. The initial stages of the disease seemed to be associated with the patient outcome: the outcome of the patients in stage IV was inferior to that of patients in stages II or III. Other clinical variables, such as relapse sites, relapse time and BM rescue did not affect the patients' outcome.
authors.affiliation: Dept. of Pediatrics, Aichi Medical University.
authors.forename: M
authors.initials: M
authors.lastname: Tsurusawa
authors.forename: N
authors.initials: N
authors.lastname: Katano
authors.forename: K
authors.initials: K
authors.lastname: Asami
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Koizumi
authors.forename: M
authors.initials: M
authors.lastname: Miyake
authors.forename: A
authors.initials: A
authors.lastname: Kikuta
authors.forename: A
authors.initials: A
authors.lastname: Iwai
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamura
authors.forename: Y
authors.initials: Y
authors.lastname: Kawano
authors.forename: H
authors.initials: H
authors.lastname: Mugishima
authors.forename: I
authors.initials: I
authors.lastname: Sekine
authors.forename: T
authors.initials: T
authors.lastname: Matsushita
authors.forename: Y
authors.initials: Y
authors.lastname: Horikoshi
authors.forename: M
authors.initials: M
authors.lastname: Kikuchi
authors.forename: K
authors.initials: K
authors.lastname: Anami
authors.forename: T
authors.initials: T
authors.lastname: Fujimoto
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; C027260:pirarubicin; D008727:Methotrexate